Payam Nahid, MD, MPH

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1001 Potrero Ave, #5J6
San Francisco CA 94110
Phone628-206-5464
ORCID ORCID Icon0000-0003-2811-1311 Additional info
vCardDownload vCard
    Other Positions
    Title(s)Director, Clinical Trials Operations


    Collapse Biography 
    Collapse Education and Training
    University of California, IrvineM.D.1997School of Medicine
    Scripps Clinic & Research FoundationResidency2001Internal Medicine
    San Diego State UniversityM.P.H.2004Epidemiology
    University of California, San FranciscoFellowship 2004Pulmonary and Critical Care Medicine
    University of California, San Francisco, San Francisco2022Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse Overview
    Dr. Nahid is Professor of Medicine, Director of Clinical Trials Operations in the UCSF Office of Research, Director of the UCSF CTSA Trials Innovation Network Hub, and Director of the UCSF Center for Tuberculosis. With over two decades of experience in global health research, he specializes in clinical trials and translational research focusing on TB and HIV/TB. In 2009, he co-founded the Vietnam National TB Program/UCSF Research Collaboration Unit, launching partnerships with the Vietnam National Lung Hospital, Hanoi Lung Hospital, and Pham Ngoc Thach Hospital in support of equitable international research activities in global health. As the UCSF Program Director and Senior Research Advisor for the USAID-funded Supporting, Mobilizing and Accelerating Research for Tuberculosis Elimination (SMART4TB) Consortium, Dr. Nahid guides the consortium’s research strategies in diagnostics, therapeutics, vaccines among other programs for combatting TB worldwide. Concurrently, he directs NIH and BMGF-funded programs focused on developing improved pharmacodynamic biomarkers for use in TB clinical trials. He is PI on NIH-funded training and mentorship programs, including the UCSF-UCB TB Research Advancement Center (UC TRAC P30), supporting domestic and international early stage investigators in research. He has expertise in implementation and delivery of new tools, and has led WHO Task Forces and international practice guidelines, and is an appointed member of the WHO Strategic and Technical Advisory Group on TB (STAG TB). Clinically, Dr. Nahid attends at ZSFG and provides consultation with the UCSF Curry International TB Center.
    Collapse Global Health Equity

    Collapse Research 
    Collapse Research Activities and Funding
    Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)
    NIH U01AI152087Aug 21, 2020 - May 31, 2025
    Role: Co-Principal Investigator
    DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial
    NIH U01AI152980Aug 21, 2020 - May 31, 2025
    Role: Principal Investigator
    TB Research And Mentorship Program (TB RAMP)
    NIH R25AI147375Aug 19, 2020 - Jul 31, 2025
    Role: Principal Investigator
    Sputum Transcriptomic Expression Profiling in Study 31: Express 31
    NIH R01AI127300Aug 3, 2017 - Jul 31, 2022
    Role: Principal Investigator
    TB Surrogate Markers for Assessing Reponse to Treatment (TB SMART Study)
    NIH R01AI104589Feb 12, 2013 - Jan 31, 2020
    Role: Principal Investigator
    Real-Time Reagent-Free Noninvasive Diagnosis of Tuberculosis
    NIH R43AI098335Jul 1, 2012 - Jun 30, 2015
    Role: Co-Principal Investigator
    Interplay of strain and ethnicity in the immune response to M. tuberculosis
    NIH K23HL092629Sep 28, 2007 - Aug 31, 2013
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications
    Collapse Collaboration Interests
    Collapse Faculty Mentoring

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa. Lancet Glob Health. 2024 Feb; 12(2):e226-e234. Gupta-Wright A, Ha H, Abdulgadar S, Crowder R, Emmanuel J, Mukwatamundu J, Marcelo D, Phillips PPJ, Christopher DJ, Nhung NV, Theron G, Yu C, Nahid P, Cattamanchi A, Worodria W, Denkinger CM, R2D2 TB Network. PMID: 38245113.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    2. Cost-effectiveness of Low-complexity Screening Tests in Community-based Case-finding for Tuberculosis. Clin Infect Dis. 2024 Jan 25; 78(1):154-163. Brümmer LE, Thompson RR, Malhotra A, Shrestha S, Kendall EA, Andrews JR, Phillips P, Nahid P, Cattamanchi A, Marx FM, Denkinger CM, Dowdy DW. PMID: 37623745; PMCID: PMC10810711.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Tuberculosis treatment monitoring tests during routine practice: study design guidance. Clin Microbiol Infect. 2024 Jan 03. MacLean EL, Zimmer AJ, Boon SD, Gupta-Wright A, Cirillo DM, Cobelens F, Gillespie SH, Nahid P, Phillips PP, Ruhwald M, Denkinger CM. PMID: 38182047.
      View in: PubMed   Mentions:    Fields:    
    4. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials. 2023 Nov 30; 24(1):773. Patil SB, Tamirat M, Khazhidinov K, Ardizzoni E, Atger M, Austin A, Baudin E, Bekhit M, Bektasov S, Berikova E, Bonnet M, Caboclo R, Chaudhry M, Chavan V, Cloez S, Coit J, Coutisson S, Dakenova Z, De Jong BC, Delifer C, Demaisons S, Do JM, Dos Santos Tozzi D, Ducher V, Ferlazzo G, Gouillou M, Khan U, Kunda M, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moreau M, Moschioni M, Nahid P, Osso E, Oyewusi L, Panda S, Pâquet A, Thuong Huu P, Pichon L, Rich ML, Rupasinghe P, Salahuddin N, Sanchez Garavito E, Seung KJ, Velásquez GE, Vallet M, Varaine F, Yuya-Septoh FJ, Mitnick CD, Guglielmetti L. PMID: 38037119; PMCID: PMC10688049.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    5. Blazing the trail for innovative tuberculosis diagnostics. Infection. 2024 Feb; 52(1):29-42. Yerlikaya S, Broger T, Isaacs C, Bell D, Holtgrewe L, Gupta-Wright A, Nahid P, Cattamanchi A, Denkinger CM. PMID: 38032537; PMCID: PMC10811035.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    6. Transcriptional adaptation of Mycobacterium tuberculosis that survives prolonged multi-drug treatment in mice. mBio. 2023 Oct 31; e0236323. Wynn EA, Dide-Agossou C, Reichlen M, Rossmassler K, Al Mubarak R, Reid JJ, Tabor ST, Born SEM, Ransom MR, Davidson RM, Walton KN, Benoit JB, Hoppers A, Loy DE, Bauman AA, Massoudi LM, Dolganov G, Strong M, Nahid P, Voskuil MI, Robertson GT, Moore CM, Walter ND. PMID: 37905920; PMCID: PMC10746229.
      View in: PubMed   Mentions:    Fields:    
    7. Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis. Lancet. 2023 Oct 21; 402(10411):1473-1498. Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Herna Sari A, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. PMID: 37716363.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials. Am J Respir Crit Care Med. 2023 05 15; 207(10):1376-1382. Kurbatova EV, Phillips PPJ, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Goldberg SV, Swindells S, Chaisson RE, Nahid P. PMID: 36790881; PMCID: PMC10595436.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    9. Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. Clin Infect Dis. 2023 05 03; 76(9):1658-1670fc. Solans BP, Béranger A, Radtke K, Mohamed A, Mirzayev F, Gegia M, Linh NN, Schumacher SG, Nahid P, Savic RM. PMID: 36609692; PMCID: PMC10156125.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    10. Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis. Am J Respir Crit Care Med. 2023 04 01; 207(7):816-818. Velásquez GE, Nahid P. PMID: 36630555; PMCID: PMC10111973.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 09; 11(9):782-790. Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. PMID: 36966788.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    12. Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis in mice. bioRxiv. 2023 Mar 08. Wynn EA, Dide-Agossou C, Reichlen M, Rossmassler K, Al Mubarak R, Reid JJ, Tabor ST, Born SEM, Ransom MR, Davidson RM, Walton KN, Benoit JB, Hoppers A, Bauman AA, Massoudi LM, Dolganov G, Nahid P, Voskuil MI, Robertson GT, Moore CM, Walter ND. PMID: 36945388; PMCID: PMC10028792.
      View in: PubMed   Mentions:
    13. Continuous cough monitoring: a novel digital biomarker for TB diagnosis and treatment response monitoring. Int J Tuberc Lung Dis. 2023 03 01; 27(3):221-222. Huddart S, Asege L, Jaganath D, Golla M, Dang H, Lovelina L, Derendinger B, Andama A, Christopher DJ, Nhung NV, Theron G, Denkinger CM, Nahid P, Cattamanchi A, Yu C. PMID: 36855045; PMCID: PMC9983626.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    14. Innovative COVID-19 point-of-care diagnostics suitable for tuberculosis diagnosis: a scoping review protocol. BMJ Open. 2023 02 08; 13(2):e065194. Yerlikaya S, Holtgrewe LM, Broger T, Isaacs C, Nahid P, Cattamanchi A, Denkinger CM. PMID: 36754560; PMCID: PMC9922875.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    15. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589. Pettit AC, Phillips PPJ, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S, Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. PMID: 36041016; PMCID: PMC10169427.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    16. Circulating Cell-Free RNA in Blood as a Host Response Biomarker for the Detection of Tuberculosis. medRxiv. 2023 Jan 11. Chang A, Loy CJ, Lenz JS, Steadman A, Andama A, Nhung NV, Yu C, Worodria W, Denkinger CM, Nahid P, Cattamanchi A, De Vlaminck I. PMID: 36711999; PMCID: PMC9882491.
      View in: PubMed   Mentions:
    17. A comparison of clinical development pathways to advance tuberculosis regimen development. BMC Infect Dis. 2022 Dec 09; 22(1):920. Chang V, Phillips PPJ, Imperial MZ, Nahid P, Savic RM. PMID: 36494644.
      View in: PubMed   Mentions:    Fields:    
    18. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clin Infect Dis. 2022 09 10; 75(4):560-566. Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips PPJ, Bryant K, Scott N, Vernon A, Kurbatova EV, Chaisson RE, Dorman SE, Nahid P, Swindells S, Dooley KE, Fletcher CV. PMID: 34918028; PMCID: PMC9890454.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    19. Accuracy of Tongue Swab Testing Using Xpert MTB-RIF Ultra for Tuberculosis Diagnosis. J Clin Microbiol. 2022 07 20; 60(7):e0042122. Andama A, Whitman GR, Crowder R, Reza TF, Jaganath D, Mulondo J, Nalugwa TK, Semitala FC, Worodria W, Cook C, Wood RC, Weigel KM, Olson AM, Lohmiller Shaw J, Kato-Maeda M, Denkinger CM, Nahid P, Cangelosi GA, Cattamanchi A. PMID: 35758702; PMCID: PMC9297831.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    20. WHO target product profiles for TB preventive treatment. Int J Tuberc Lung Dis. 2022 04 01; 26(4):302-309. Den Boon S, Lienhardt C, Zignol M, Schwartzman K, Arinaminpathy N, Campbell JR, Nahid P, Penazzato M, Menzies D, Vesga JF, Oxlade O, Churchyard G, Merle CS, Kasaeva T, Falzon D. PMID: 35351234; PMCID: PMC7612716.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    21. Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments. Antimicrob Agents Chemother. 2022 04 19; 66(4):e0231021. Dide-Agossou C, Bauman AA, Ramey ME, Rossmassler K, Al Mubarak R, Pauly S, Voskuil MI, Garcia-Cremades M, Savic RM, Nahid P, Moore CM, Tasneen R, Nuermberger EL, Robertson GT, Walter ND. PMID: 35311519; PMCID: PMC9017352.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    22. Interventions to enhance treatment adherence and retention in care for HIV-TB. Int J Tuberc Lung Dis. 2022 03 01; 26(3):279-281. Hudson M, Alipanah N, Singh S, Nahid P. PMID: 35197169.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Overseas Treatment of Latent Tuberculosis Infection in US-Bound Immigrants. Emerg Infect Dis. 2022 03; 28(3):582-590. Khan A, Phares CR, Phuong HL, Trinh DTK, Phan H, Merrifield C, Le PTH, Lien QTK, Lan SN, Thoa PTK, Thu LTM, Tran T, Tran C, Platt L, Maloney SA, Nhung NV, Nahid P, Oeltmann JE. PMID: 35195518; PMCID: PMC8888219.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    24. The scientific response to TB - the other deadly global health emergency. Int J Tuberc Lung Dis. 2022 03 01; 26(3):186-189. Chaisson RE, Frick M, Nahid P. PMID: 35197158; PMCID: PMC8886961.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    25. MOVER approximated CV: A tool for quantifying precision in ratiometric droplet digital PCR assays. J Pharm Biomed Anal. 2022 Apr 01; 212:114664. Dide-Agossou C, Rossmassler K, Reid J, Purohit J, Savic RM, Nahid P, Phillips PPJ, Moore CM, Walter ND. PMID: 35192991; PMCID: PMC8923918.
      View in: PubMed   Mentions:    Fields:    
    26. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 12; 18(12):e1003875. Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. PMID: 34914696; PMCID: PMC8726462.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Indoor Air Pollution and Susceptibility to Tuberculosis Infection in Urban Vietnamese Children. Am J Respir Crit Care Med. 2021 11 15; 204(10):1211-1221. Blount RJ, Phan H, Trinh T, Dang H, Merrifield C, Zavala M, Zabner J, Comellas AP, Stapleton EM, Segal MR, Balmes J, Nhung NV, Nahid P. PMID: 34343025; PMCID: PMC8759300.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    28. Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials. Am J Respir Crit Care Med. 2021 11 01; 204(9):1086-1096. Imperial MZ, Phillips PPJ, Nahid P, Savic RM. PMID: 34346856; PMCID: PMC8663006.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    29. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021 10 01; 25(10):797-813. Migliori GB, Marx FM, Ambrosino N, Zampogna E, Schaaf HS, van der Zalm MM, Allwood B, Byrne AL, Mortimer K, Wallis RS, Fox GJ, Leung CC, Chakaya JM, Seaworth B, Rachow A, Marais BJ, Furin J, Akkerman OW, Al Yaquobi F, Amaral AFS, Borisov S, Caminero JA, Carvalho ACC, Chesov D, Codecasa LR, Teixeira RC, Dalcolmo MP, Datta S, Dinh-Xuan AT, Duarte R, Evans CA, García-García JM, Günther G, Hoddinott G, Huddart S, Ivanova O, Laniado-Laborín R, Manga S, Manika K, Mariandyshev A, Mello FCQ, Mpagama SG, Muñoz-Torrico M, Nahid P, Ong CWM, Palmero DJ, Piubello A, Pontali E, Silva DR, Singla R, Spanevello A, Tiberi S, Udwadia ZF, Vitacca M, Centis R, D Ambrosio L, Sotgiu G, Lange C, Visca D. PMID: 34615577; PMCID: PMC8504493.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    30. Reproducibility of the Ribosomal RNA Synthesis Ratio in Sputum and Association with Markers of Mycobacterium tuberculosis Burden. Microbiol Spectr. 2021 10 31; 9(2):e0048121. Musisi E, Dide-Agossou C, Al Mubarak R, Rossmassler K, Ssesolo AW, Kaswabuli S, Byanyima P, Sanyu I, Zawedde J, Worodria W, Voskuil MI, Savic RM, Nahid P, Davis JL, Huang L, Moore CM, Walter ND. PMID: 34494858; PMCID: PMC8557932.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    31. A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials. Trials. 2021 Aug 03; 22(1):515. Hills NK, Lyimo J, Nahid P, Savic RM, Lienhardt C, Phillips PPJ. PMID: 34344435; PMCID: PMC8329622.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    32. Mycobacterium tuberculosis precursor rRNA as a measure of treatment-shortening activity of drugs and regimens. Nat Commun. 2021 05 18; 12(1):2899. Walter ND, Born SEM, Robertson GT, Reichlen M, Dide-Agossou C, Ektnitphong VA, Rossmassler K, Ramey ME, Bauman AA, Ozols V, Bearrows SC, Schoolnik G, Dolganov G, Garcia B, Musisi E, Worodria W, Huang L, Davis JL, Nguyen NV, Nguyen HV, Nguyen ATV, Phan H, Wilusz C, Podell BK, Sanoussi ND, de Jong BC, Merle CS, Affolabi D, McIlleron H, Garcia-Cremades M, Maidji E, Eshun-Wilson F, Aguilar-Rodriguez B, Karthikeyan D, Mdluli K, Bansbach C, Lenaerts AJ, Savic RM, Nahid P, Vásquez JJ, Voskuil MI. PMID: 34006838; PMCID: PMC8131613.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    33. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 05 06; 384(18):1705-1718. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE, AIDS Clinical Trials Group, Tuberculosis Trials Consortium. PMID: 33951360; PMCID: PMC8282329.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansCellsCTClinical Trials
    34. Nutritional markers and proteome in patients undergoing treatment for pulmonary tuberculosis differ by geographic region. PLoS One. 2021; 16(5):e0250586. Jarsberg LG, Kedia K, Wendler J, Wright AT, Piehowski PD, Gritsenko MA, Shi T, Lewinsohn DM, Sigal GB, Weiner MH, Smith RD, Keane J, Jacobs JM, Nahid P. PMID: 33951066; PMCID: PMC8099102.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    35. Reply to Chang and Yew. Am J Respir Crit Care Med. 2020 09 01; 202(5):778-779. Sotgiu G, Battista Migliori G, Menzies D, Mase S, Chorba T, Seaworth B, Nahid P. PMID: 32374628; PMCID: PMC7462397.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 08 12; 15(1):65. Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. PMID: 32787925; PMCID: PMC7425004.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    37. Summary for Clinicians: 2019 Clinical Practice Guideline Summary for the Treatment of Drug-Resistant Tuberculosis. Ann Am Thorac Soc. 2020 08; 17(8):911-917. Berger CA, Alipanah N, Kheir F, Ruminjo JK, Nahid P, Thomson C. PMID: 32464069.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    38. Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection. J Clin Microbiol. 2020 05 26; 58(6). Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM. PMID: 32245831; PMCID: PMC7269374.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    39. The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis. Eur Respir J. 2020 03; 55(3). Cegielski JP, Nahid P, Sotgiu G. PMID: 32198274.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    40. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020 04; 8(4):383-394. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017. PMID: 32192585; PMCID: PMC7384398.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    41. Triumph and Tragedy of 21st Century Tuberculosis Drug Development. N Engl J Med. 2020 03 05; 382(10):959-960. Thwaites G, Nahid P. PMID: 32130819.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    42. Advances in clinical trial design: Weaving tomorrow's TB treatments. PLoS Med. 2020 02; 17(2):e1003059. Lienhardt C, Nunn A, Chaisson R, Vernon AA, Zignol M, Nahid P, Delaporte E, Kasaeva T. PMID: 32106220; PMCID: PMC7046183.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    43. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020 03; 90:105938. Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE, AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. PMID: 31981713; PMCID: PMC7307310.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    44. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials. PLoS Med. 2019 12; 16(12):e1002884. Vernon A, Fielding K, Savic R, Dodd L, Nahid P. PMID: 31821323; PMCID: PMC6903706.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    45. Treatment of Drug-Susceptible Tuberculosis. Clin Chest Med. 2019 12; 40(4):763-774. Zha BS, Nahid P. PMID: 31731983.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    46. Residential urban tree canopy is associated with decreased mortality during tuberculosis treatment in California. Sci Total Environ. 2020 Apr 01; 711:134580. Blount RJ, Pascopella L, Barry P, Zabner J, Stapleton EM, Flood J, Balmes J, Nahid P, Catanzaro DG. PMID: 32000313; PMCID: PMC6995452.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsPHPublic Health
    47. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019 11 15; 200(10):e93-e142. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. PMID: 31729908; PMCID: PMC6857485.
      View in: PubMed   Mentions: 134     Fields:    Translation:Humans
    48. Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance. PLoS Med. 2019 09; 16(9):e1002915. Lienhardt C, Vernon AA, Cavaleri M, Nambiar S, Nahid P. PMID: 31490921; PMCID: PMC6730844.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    49. Multidrug-resistant tuberculosis - Authors' reply. Lancet. 2019 07 27; 394(10195):299-300. Menzies D, Benedetti A, Migliori GB, Nahid P, Seaworth B. PMID: 31354139.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening. Diagnostics (Basel). 2019 May 30; 9(2). Alipanah N, Shete PB, Nguyen H, Nguyen NV, Luu L, Pham T, Nguyen H, Nguyen P, Tran MC, Pham N, Phan H, Phillips PPJ, Cattamanchi A, Nahid P. PMID: 31151255; PMCID: PMC6627302.
      View in: PubMed   Mentions: 2  
    51. Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients. PLoS One. 2019; 14(4):e0215443. Broger T, Tsionksy M, Mathew A, Lowary TL, Pinter A, Plisova T, Bartlett D, Barbero S, Denkinger CM, Moreau E, Katsuragi K, Kawasaki M, Nahid P, Sigal GB. PMID: 30998715; PMCID: PMC6472883.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsCTClinical Trials
    52. Advances in clinical trial design for development of new TB treatments: A call for innovation. PLoS Med. 2019 03; 16(3):e1002769. Lienhardt C, Nahid P. PMID: 30901322; PMCID: PMC6430361.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    53. Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. PLoS Med. 2019 03; 16(3):e1002767. Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ. PMID: 30901331; PMCID: PMC6430373.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    54. Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection. Am J Respir Crit Care Med. 2019 03 01; 199(5):564-571. Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P. PMID: 30335466; PMCID: PMC6396859.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    55. Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2019 Jan; 25(1):190. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. PMID: 30429542; PMCID: PMC7608289.
      View in: PubMed   Mentions: 1     Fields:    
    56. A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis. J Clin Microbiol. 2018 12; 56(12). Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, Tsionsky M, Zheng RB, Plisova T, Shen K, Katsuragi K, Choudhary A, Honnen WJ, Nahid P, Denkinger CM, Broger T. PMID: 30257899; PMCID: PMC6258851.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    57. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018 11; 24(11):1708-1715. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. PMID: 30397355; PMCID: PMC6685538.
      View in: PubMed   Mentions: 125     Fields:    Translation:HumansCTClinical Trials
    58. The association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patients. Clin Respir J. 2018 Nov; 12(11):2590-2597. Korkmaz Ekren P, Töreyin ZN, Nahid P, Doskaya M, Caner A, Turgay N, Zeytinoglu A, Toz S, Bacakoglu F, Guruz Y, Erensoy S. PMID: 30244544.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    59. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 09 08; 392(10150):821-834. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D. PMID: 30215381; PMCID: PMC6463280.
      View in: PubMed   Mentions: 234     Fields:    Translation:Humans
    60. Tuberculosis. Emergency Management of Infectious Diseases. 2018 Aug 9; 308-318. Blount BR, Nahid NP, Cattamanchi CA. .
      View in: Publisher Site   Mentions:
    61. Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis. Tuberculosis (Edinb). 2018 09; 112:52-61. Kedia K, Wendler JP, Baker ES, Burnum-Johnson KE, Jarsberg LG, Stratton KG, Wright AT, Piehowski PD, Gritsenko MA, Lewinsohn DM, Sigal GB, Weiner MH, Smith RD, Jacobs JM, Nahid P. PMID: 30205969; PMCID: PMC6181582.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    62. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018 07; 15(7):e1002595. Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P. PMID: 29969463; PMCID: PMC6029765.
      View in: PubMed   Mentions: 157     Fields:    Translation:Humans
    63. Does discovery of differentially culturable M tuberculosis really demand a new treatment paradigm? Longitudinal analysis of DNA clearance from sputum. BMC Infect Dis. 2018 07 03; 18(1):293. Walter ND, Moore CM, Kayigire XA, Dide-Agossou C, Worodria W, Huang L, Everett CK, Schoolnik GS, Nahid P, Davis JL. PMID: 29970012; PMCID: PMC6029172.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    64. Interplay of strain and race/ethnicity in the innate immune response to M. tuberculosis. PLoS One. 2018; 13(5):e0195392. Nahid P, Jarlsberg LG, Kato-Maeda M, Segal MR, Osmond DH, Gagneux S, Dobos K, Gold M, Hopewell PC, Lewinsohn DM. PMID: 29787561; PMCID: PMC5963792.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    65. Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial. EBioMedicine. 2017 Nov; 25:112-121. Sigal GB, Segal MR, Mathew A, Jarlsberg L, Wang M, Barbero S, Small N, Haynesworth K, Davis JL, Weiner M, Whitworth WC, Jacobs J, Schorey J, Lewinsohn DM, Nahid P. PMID: 29100778; PMCID: PMC5704068.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    66. Traffic-Related Air Pollution and All-Cause Mortality during Tuberculosis Treatment in California. Environ Health Perspect. 2017 09 29; 125(9):097026. Blount RJ, Pascopella L, Catanzaro DG, Barry PM, English PB, Segal MR, Flood J, Meltzer D, Jones B, Balmes J, Nahid P. PMID: 28963088; PMCID: PMC5915191.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    67. Second generation multiple reaction monitoring assays for enhanced detection of ultra-low abundance Mycobacterium tuberculosis peptides in human serum. Clin Proteomics. 2017; 14:21. Mehaffy C, Dobos KM, Nahid P, Kruh-Garcia NA. PMID: 28592925; PMCID: PMC5460347.
      View in: PubMed   Mentions: 23  
    68. Clinical and bacteriological characteristics associated with clustering of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2017 07 01; 21(7):766-773. Feng JY, Jarlsberg LG, Salcedo K, Rose J, Janes M, Lin SG, Osmond DH, Jost KC, Soehnlen MK, Flood J, Graviss EA, Desmond E, Moonan PK, Nahid P, Hopewell PC, Kato-Maeda M. PMID: 28513421; PMCID: PMC6643968.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    69. Impact of Euro-American sublineages of Mycobacterium tuberculosis on new infections among named contacts. Int J Tuberc Lung Dis. 2017 05 01; 21(5):509-516. Feng JY, Jarlsberg LG, Rose J, Grinsdale JA, Janes M, Higashi J, Osmond DH, Nahid P, Hopewell PC, Kato-Maeda M. PMID: 28399965.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    70. Vitamin D Deficiency in Patients Referred for Evaluation of Obstructive Sleep Apnea. J Clin Sleep Med. 2017 Apr 15; 13(4):607-612. Salepci B, Caglayan B, Nahid P, Parmaksiz ET, Kiral N, Fidan A, Comert SS, Dogan C, Gungor GA. PMID: 27998376; PMCID: PMC5359338.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    71. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017 Mar 15. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. PMID: 28344011.
      View in: PubMed   Mentions: 244     Fields:    
    72. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther. 2017 Aug; 102(2):321-331. Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE, Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. PMID: 28124478; PMCID: PMC5545752.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    73. First in vivo magnetic particle imaging of lung perfusion in rats. Phys Med Biol. 2017 05 07; 62(9):3510-3522. Zhou XY, Jeffris KE, Yu EY, Zheng B, Goodwill PW, Nahid P, Conolly SM. PMID: 28218614; PMCID: PMC5734624.
      View in: PubMed   Mentions: 39     Fields:    Translation:Animals
    74. Target regimen profiles for treatment of tuberculosis: a WHO document. Eur Respir J. 2017 01; 49(1). Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M. PMID: 28122858; PMCID: PMC5509341.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    75. Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model. PLoS Med. 2017 Jan; 14(1):e1002202. Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. PMID: 28045934; PMCID: PMC5207633.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansPHPublic Health
    76. Tuberculosis Treatment. International Encyclopedia of Public Health. 2017 Jan 1; 267-276. Nahid NP, Hopewell HP. .
      View in: Publisher Site   Mentions:
    77. Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis. Int J Tuberc Lung Dis. 2016 11; 20(11):1522-1528. Alipanah N, Cattamanchi A, Menzies R, Hopewell PC, Chaisson RE, Nahid P. PMID: 27776595.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    78. Treatment of Drug-Susceptible Tuberculosis. Ann Am Thorac Soc. 2016 11; 13(11):2060-2063. Dela Cruz CS, Lyons PG, Pasnick S, Weinstock T, Nahid P, Wilson KC, Thomson CC. PMID: 27831799.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    79. Reply to Alffenaar et al. Clin Infect Dis. 2017 01 01; 64(1):105-106. Peloquin CA, Dorman SE, Vernon A, Battista Migliori G, Nahid P. PMID: 27789610.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure. J Clin Microbiol. 2016 12; 54(12):3028-3033. Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P. PMID: 27733634; PMCID: PMC5121396.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    81. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 10 01; 63(7):853-67. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. PMID: 27621353; PMCID: PMC6366011.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCellsPHPublic Health
    82. The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis. Eur Respir J. 2016 10; 48(4):963-971. Sotgiu G, Nahid P, Loddenkemper R, Abubakar I, Miravitlles M, Migliori GB. PMID: 27587550.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    83. Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays. BMC Public Health. 2016 08 25; 16(1):875. Blount RJ, Tran MC, Everett CK, Cattamanchi A, Metcalfe JZ, Connor D, Miller CR, Grinsdale J, Higashi J, Nahid P. PMID: 27558397; PMCID: PMC4997768.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    84. Urban tree coverage associated with reduced mortality among tuberculosis (TB) patients undergoing treatment in California. ISEE Conference Abstracts. 2016 Aug 17; 2016(1). Blount* BR, Pascopella PL, Barry BP, Meltzer MD, Flood FJ, English EP, Segal SM, Nahid NP, Balmes BJ, Catanzaro CD. .
      View in: Publisher Site   Mentions:
    85. Adaptation of Mycobacterium tuberculosis to Impaired Host Immunity in HIV-Infected Patients. J Infect Dis. 2016 10 15; 214(8):1205-11. Walter ND, de Jong BC, Garcia BJ, Dolganov GM, Worodria W, Byanyima P, Musisi E, Huang L, Chan ED, Van TT, Antonio M, Ayorinde A, Kato-Maeda M, Nahid P, Leung AM, Yen A, Fingerlin TE, Kechris K, Strong M, Voskuil MI, Davis JL, Schoolnik GK. PMID: 27534685; PMCID: PMC5034964.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    86. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016 10 01; 63(7):e147-e195. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. PMID: 27516382; PMCID: PMC6590850.
      View in: PubMed   Mentions: 368     Fields:    Translation:HumansCellsPHPublic Health
    87. A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Med. 2016 Mar 23; 14:51. Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M. PMID: 27004726; PMCID: PMC4804526.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    88. Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults. Int J Tuberc Lung Dis. 2016 Mar; 20(3):290-4. Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P. PMID: 27046707; PMCID: PMC4843774.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    89. Challenges in the clinical assessment of novel tuberculosis drugs. Adv Drug Deliv Rev. 2016 07 01; 102:116-22. Dooley KE, Phillips PP, Nahid P, Hoelscher M. PMID: 26827911; PMCID: PMC4903928.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    90. A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis. Clin Infect Dis. 2015 Oct 15; 61Suppl 3:S164-72. Nicol MP, Gnanashanmugam D, Browning R, Click ES, Cuevas LE, Detjen A, Graham SM, Levin M, Makhene M, Nahid P, Perez-Velez CM, Reither K, Song R, Spiegel HM, Worrell C, Zar HJ, Walzl G. PMID: 26409279; PMCID: PMC4583573.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    91. Evaluation of mobile digital light-emitting diode fluorescence microscopy in Hanoi, Viet Nam. Int J Tuberc Lung Dis. 2015 Sep; 19(9):1068-72. Chaisson LH, Reber C, Phan H, Switz N, Nilsson LM, Myers F, Nhung NV, Luu L, Pham T, Vu C, Nguyen H, Nguyen A, Dinh T, Nahid P, Fletcher DA, Cattamanchi A. PMID: 26260826.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    92. In vitro immunomodulation for enhancing T cell-based diagnosis of Mycobacterium tuberculosis infection. Diagn Microbiol Infect Dis. 2015 Sep; 83(1):41-5. Slater M, Tran MC, Platt L, Luu LT, Phan HT, Pham PT, Do TB, Nguyen HT, Gaur RL, Parsonnet J, Cattamanchi A, Luo R, Nahid P, Banaei N. PMID: 26081239; PMCID: PMC5480369.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    93. Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis. Tuberculosis (Edinb). 2015 Jul; 95(4):415-20. Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P, Tuberculosis Trials Consortium. PMID: 26022314; PMCID: PMC4521594.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    94. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015 Apr; 45(4):928-52. Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunovic A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC. PMID: 25792630; PMCID: PMC4391660.
      View in: PubMed   Mentions: 261     Fields:    Translation:HumansPHPublic Health
    95. Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis. J Infect Dis. 2015 Sep 15; 212(6):990-8. Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris K, Palmer C, Nahid P, Daley CL, Geraci M, Huang L, Cattamanchi A, Strong M, Schoolnik GK, Davis JL. PMID: 25762787; PMCID: PMC4548467.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCells
    96. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015 Feb 01; 191(3):333-43. Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M, Tuberculosis Trials Consortium. PMID: 25489785; PMCID: PMC5447287.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    97. Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS. PLoS One. 2014; 9(7):e103811. Kruh-Garcia NA, Wolfe LM, Chaisson LH, Worodria WO, Nahid P, Schorey JS, Davis JL, Dobos KM. PMID: 25080351; PMCID: PMC4117584.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCells
    98. Non-tuberculous mycobacterial infections at San Francisco General Hospital. Clin Respir J. 2015 Oct; 9(4):436-42. Sheu LC, Tran TM, Jarlsberg LG, Marras TK, Daley CL, Nahid P. PMID: 24799125.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    99. Childhood tuberculosis in northern Viet Nam: a review of 103 cases. PLoS One. 2014; 9(5):e97267. Blount RJ, Tran B, Jarlsberg LG, Phan H, Thanh Hoang V, Nguyen NV, Lewinsohn DA, Nahid P. PMID: 24818967; PMCID: PMC4018290.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    100. Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California. PLoS One. 2014; 9(4):e95645. Budzik JM, Jarlsberg LG, Higashi J, Grinsdale J, Hopewell PC, Kato-Maeda M, Nahid P. PMID: 24759760; PMCID: PMC3997554.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    101. Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):551-6. Yoon C, Davis JL, Huang L, Muzoora C, Byakwaga H, Scibetta C, Bangsberg DR, Nahid P, Semitala FC, Hunt PW, Martin JN, Cattamanchi A. PMID: 24346636; PMCID: PMC3999220.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    102. Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis (Edinb). 2014 May; 94(3):187-96. Nahid P, Bliven-Sizemore E, Jarlsberg LG, De Groote MA, Johnson JL, Muzanyi G, Engle M, Weiner M, Janjic N, Sterling DG, Ochsner UA. PMID: 24629635; PMCID: PMC4028389.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    103. Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc. 2014 Sep; 3(3):221-7. Chang SH, Nahid P, Eitzman SR. PMID: 26625385.
      View in: PubMed   Mentions: 8     Fields:    
    104. Factors associated with failure to complete isoniazid therapy for latent tuberculosis infection in children and adolescents. J Infect Public Health. 2014 Mar-Apr; 7(2):145-52. Chang SH, Eitzman SR, Nahid P, Finelli ML. PMID: 24361084.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    105. Update in tuberculosis and nontuberculous mycobacterial disease 2012. Am J Respir Crit Care Med. 2013 Oct 15; 188(8):923-7. Menzies D, Nahid P. PMID: 24127799.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    106. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013 May; 12(5):388-404. Zumla A, Nahid P, Cole ST. PMID: 23629506.
      View in: PubMed   Mentions: 273     Fields:    Translation:HumansCells
    107. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One. 2013; 8(4):e61002. De Groote MA, Nahid P, Jarlsberg L, Johnson JL, Weiner M, Muzanyi G, Janjic N, Sterling DG, Ochsner UA. PMID: 23637781; PMCID: PMC3630118.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    108. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013 Jun; 13(6):529-39. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A. PMID: 23531391.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCells
    109. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis. 2012 Oct 01; 206(7):1030-40. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW, Tuberculosis Trials Consortium. PMID: 22850121.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCellsCTClinical Trials
    110. Update in tuberculosis and nontuberculous mycobacterial disease 2011. Am J Respir Crit Care Med. 2012 Jun 15; 185(12):1266-70. Nahid P, Menzies D. PMID: 22707733.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsPHPublic Health
    111. Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis. PLoS One. 2012; 7(5):e37956. Dantes R, Metcalfe J, Kim E, Kato-Maeda M, Hopewell PC, Kawamura M, Nahid P, Cattamanchi A. PMID: 22649569; PMCID: PMC3359338.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    112. Clinical research and development of tuberculosis diagnostics: moving from silos to synergy. J Infect Dis. 2012 May 15; 205 Suppl 2:S159-68. Nahid P, Kim PS, Evans CA, Alland D, Barer M, Diefenbach J, Ellner J, Hafner R, Hamilton CD, Iademarco MF, Ireton G, Kimerling ME, Lienhardt C, MacKenzie WR, Murray M, Perkins MD, Posey JE, Roberts T, Sizemore C, Stevens WS, Via L, Williams SD, Yew WW, Swindells S. PMID: 22476718; PMCID: PMC3334509.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    113. Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. Tuberculosis (Edinb). 2012 May; 92(3):243-7. Goodridge A, Cueva C, Lahiff M, Muzanye G, Johnson JL, Nahid P, Riley LW. PMID: 22406155; PMCID: PMC4408545.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    114. Mycobacterium tuberculosis lineage--what's in your lungs? Clin Infect Dis. 2012 Jan 15; 54(2):220-4. Kato-Maeda M, Nahid P. PMID: 22198990; PMCID: PMC3245729.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    115. Mycobacterial Infections in the non-HIV–Infected Patient. . 2012 Jan 1; 1478-1485. Nyendak NM, Eid ET, Nahid NP, Winthrop WK, Lewinsohn LD. .
      View in: Publisher Site   Mentions:
    116. Major Radiation Exposure. . 2012 Jan 1; 1351-1351. Bensard BD, Stahel SP, Cerdá CJ, Sarani SB, Shahul SS, Talmor TD, Hammer HP, Schwab SC, Reynolds RS, Ahmad AO, Kaneko KT, Estrera EA, Knight KW, Dixon DB, Gamelli GR, Posluszny PJ, Bangash BM, Pearse PR, Ruggieri RA, Levy LR, Deutschman DC, Deutschman DC, Levy LR, Mohan Rao MP, Kress KJ, Scolletta SS, McSwain MN, Kashuk KJ, Sauaia SA, Moore ME, Hasselgren HP, Smith SW, Riehl RJ, Bensard BD, Stahel SP, Moed MB, Bieneman BB, Moed MB, Cothren CC, Moore ME, Majlesi MN, Shih SR, Wijdicks WE, Nyendak NM, Eid ET, Nahid NP, Winthrop WK, Lewinsohn LD, Chou CJ, Lim LT, Lee LA, Mody MC, Lim LT, Chou CJ, Mody MC, Mowery MN, Colonna CA, Meredith MJ, Combes CA, Egan EJ, Festa FM, Montcriol MA, Asencio AY, Kerbaul KF. .
      View in: Publisher Site   Mentions:
    117. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med. 2011 Oct 15; 184(8):972-9. Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W, National Institutes of Health, Centers for Disease Control and Prevention. PMID: 21737585; PMCID: PMC3208659.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    118. Racial differences in tuberculosis infection in United States communities: the coronary artery risk development in young adults study. Clin Infect Dis. 2011 Aug 01; 53(3):291-4. Nahid P, Horne DJ, Jarlsberg LG, Reiner AP, Osmond D, Hopewell PC, Bibbins-Domingo K. PMID: 21765079; PMCID: PMC3137794.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    119. Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb). 2011 May; 91(3):250-6. Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, Cadogan E, Nahid P, Ferrari G, Stout JE. PMID: 21393062; PMCID: PMC3090479.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    120. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2011 Mar; 15(3):305-16. Steingart KR, Jotblad S, Robsky K, Deck D, Hopewell PC, Huang D, Nahid P. PMID: 21333096.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    121. Sputum monitoring during tuberculosis treatment for predicting outcome Authors' reply. The Lancet Infectious Diseases. 2011 Mar 1; 11(3):160-161. Horne HD, Royce RS, Narita NM, Nahid NP, Steingart SK. .
      View in: Publisher Site   Mentions:
    122. Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis. 2011 Jan 03; 11:1. Nahid P, Jarlsberg LG, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL. PMID: 21199579; PMCID: PMC3022714.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    123. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010 Jun; 10(6):387-94. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, Steingart KR. PMID: 20510279; PMCID: PMC3046810.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCells
    124. Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One. 2010 May 20; 5(5):e10753. Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M, Tuberculosis Trials Consortium. PMID: 20505778; PMCID: PMC2873999.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    125. Novel hot spot of IS6110 insertion in Mycobacterium tuberculosis. J Clin Microbiol. 2010 Apr; 48(4):1422-4. Kim EY, Nahid P, Hopewell PC, Kato-Maeda M. PMID: 20147648; PMCID: PMC2849554.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    126. Evaluation of quantitative IFN-gamma response for risk stratification of active tuberculosis suspects. Am J Respir Crit Care Med. 2010 Jan 01; 181(1):87-93. Metcalfe JZ, Cattamanchi A, Vittinghoff E, Ho C, Grinsdale J, Hopewell PC, Kawamura LM, Nahid P. PMID: 19797760; PMCID: PMC2797629.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    127. Relapse associated with active disease caused by Beijing strain of Mycobacterium tuberculosis. Emerg Infect Dis. 2009 Jul; 15(7):1061-7. Burman WJ, Bliven EE, Cowan L, Bozeman L, Nahid P, Diem L, Vernon A, Tuberculosis Trials Consortium. PMID: 19624921; PMCID: PMC2744226.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    128. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis. 2009 Jan 15; 48(2):179-85. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, Osmond D, Hopewell PC, Nahid P. PMID: 19086909; PMCID: PMC2756509.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCells
    129. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol. 2009 Feb; 16(2):260-76. Steingart KR, Dendukuri N, Henry M, Schiller I, Nahid P, Hopewell PC, Ramsay A, Pai M, Laal S. PMID: 19052159; PMCID: PMC2643545.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCells
    130. Detailed analysis of the radiographic presentation of Mycobacterium kansasii lung disease in patients with HIV infection. Chest. 2008 Apr; 133(4):875-80. Cattamanchi A, Nahid P, Marras TK, Gotway MB, Lee TJ, Gonzalez LC, Morris A, Webb WR, Osmond DH, Daley CL. PMID: 18263685.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    131. Tuberculosis Treatment. International Encyclopedia of Public Health. 2008 Jan 1; 397-408. Nahid NP, Hopewell HP. .
      View in: Publisher Site   Mentions:
    132. Tuberculosis. Emergency Management of Infectious Diseases. 2008 Jan 1; 175-184. Cattamanchi CA, Nahid NP. .
      View in: Publisher Site   Mentions:
    133. On Treatment Outcomes of Patients with HIV and Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2008 Jan 1; 177(1):121-122. Nahid NP, de Jong dB, Daley DC. .
      View in: Publisher Site   Mentions:
    134. Efficacy of nurse case-managed intervention for latent tuberculosis among homeless subsamples. Nurs Res. 2008 Jan-Feb; 57(1):33-9. Nyamathi A, Nahid P, Berg J, Burrage J, Christiani A, Aqtash S, Morisky D, Leake B. PMID: 18091290; PMCID: PMC3100804.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    135. Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective. Clin Infect Dis. 2008 Jan 01; 46(1):103-6. Walter ND, Jasmer RM, Grinsdale J, Kawamura LM, Hopewell PC, Nahid P. PMID: 18171222.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    136. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med. 2007 Jun 01; 175(11):1199-206. Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL. PMID: 17290042; PMCID: PMC1899273.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    137. Unusual finding on bronchoscopy: trauma patient identified as a body stuffer. J Clin Anesth. 2006 Dec; 18(8):628-30. Chang C, Grush A, McClintock DE, Nahid P, Tang JF. PMID: 17175436.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    138. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis. 2006 Jul; 10(7):775-82. Nyamathi AM, Christiani A, Nahid P, Gregerson P, Leake B. PMID: 16848340.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    139. Prevention of tuberculosis in HIV-infected patients. Curr Opin Infect Dis. 2006 Apr; 19(2):189-93. Nahid P, Daley CL. PMID: 16514345.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    140. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc. 2006; 3(1):103-10. Nahid P, Pai M, Hopewell PC. PMID: 16493157; PMCID: PMC2658675.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    141. Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002 Dec 05; 347(23):1860-6. Jasmer RM, Nahid P, Hopewell PC. PMID: 12466511.
      View in: PubMed   Mentions: 109     Fields:    Translation:Humans